OPINION CHANGE
CHANGE IN OPINIONBuy vs Reduce
CHANGE IN EPS2015 : € -0.13 vs -0.13
2016 : € -0.25 vs -0.27 ns
Due to the new funding from Bpi France (€5m), we have decreased the financial expenses, leading to a slight increase in EPS 2016.
CHANGE IN NAV€ 1.87 vs 1.34 +39.8%
We have revised up the valuation for IFN Kinoide after the partnership signed in late 2015, with a positive impact from 2016. This partnership strengthens the likelihood of success in Lupus and dermatomyositis, ....
06 Jan 2016
Opinion change, from Reduce to Buy (Neovacs)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Opinion change, from Reduce to Buy (Neovacs)
Neovacs SA (0W8U:LON) | 0 0 0.4% | Mkt Cap: 32.4m
- Published:
06 Jan 2016 -
Author:
Armelle Moulin -
Pages:
2
OPINION CHANGE
CHANGE IN OPINIONBuy vs Reduce
CHANGE IN EPS2015 : € -0.13 vs -0.13
2016 : € -0.25 vs -0.27 ns
Due to the new funding from Bpi France (€5m), we have decreased the financial expenses, leading to a slight increase in EPS 2016.
CHANGE IN NAV€ 1.87 vs 1.34 +39.8%
We have revised up the valuation for IFN Kinoide after the partnership signed in late 2015, with a positive impact from 2016. This partnership strengthens the likelihood of success in Lupus and dermatomyositis, ....